The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigation and evaluation of novel agents that target cellular pathw...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/435342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524590181875712 |
|---|---|
| author | Pinelopi Argyriou Panagiota Economopoulou Sotirios Papageorgiou |
| author_facet | Pinelopi Argyriou Panagiota Economopoulou Sotirios Papageorgiou |
| author_sort | Pinelopi Argyriou |
| collection | DOAJ |
| description | Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigation and evaluation of novel agents that target cellular pathways. The mammalian target of rapamycin (mTOR) is a representative pathway that may be implicated in lymphomagenesis. Rapamycin and especially its derivatives (temsirolimus, everolimus, and deforolimus) represent the first described mTOR inhibitors. These agents have shown promising results in the treatment of lymphoid malignancies. On the other hand, new ATP-competitive mTOR inhibitors that provoke a broader inhibition of mTOR activity are in early stages of clinical development. The purpose of this paper is to summarize the existing knowledge about mTOR inhibitors and their use in the treatment of B-cell lymphomas. Relevant issues regarding mTOR biology in general as well as in B-cell lymphoid neoplasms are also discussed in short. |
| format | Article |
| id | doaj-art-038d661acb6f4364b168d1dd0673f79a |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-038d661acb6f4364b168d1dd0673f79a2025-02-03T05:52:47ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/435342435342The Role of mTOR Inhibitors for the Treatment of B-Cell LymphomasPinelopi Argyriou0Panagiota Economopoulou1Sotirios Papageorgiou2Department of Pathology, “Evangelismos” General Hospital of Athens, Athens, GreeceHaematology Unit, Second Department of Internal Medicine—Propaedeutic, University General Hospital “Attikon”, GreeceHaematology Unit, Second Department of Internal Medicine—Propaedeutic, University General Hospital “Attikon”, GreeceDespite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigation and evaluation of novel agents that target cellular pathways. The mammalian target of rapamycin (mTOR) is a representative pathway that may be implicated in lymphomagenesis. Rapamycin and especially its derivatives (temsirolimus, everolimus, and deforolimus) represent the first described mTOR inhibitors. These agents have shown promising results in the treatment of lymphoid malignancies. On the other hand, new ATP-competitive mTOR inhibitors that provoke a broader inhibition of mTOR activity are in early stages of clinical development. The purpose of this paper is to summarize the existing knowledge about mTOR inhibitors and their use in the treatment of B-cell lymphomas. Relevant issues regarding mTOR biology in general as well as in B-cell lymphoid neoplasms are also discussed in short.http://dx.doi.org/10.1155/2012/435342 |
| spellingShingle | Pinelopi Argyriou Panagiota Economopoulou Sotirios Papageorgiou The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas Advances in Hematology |
| title | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| title_full | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| title_fullStr | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| title_full_unstemmed | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| title_short | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| title_sort | role of mtor inhibitors for the treatment of b cell lymphomas |
| url | http://dx.doi.org/10.1155/2012/435342 |
| work_keys_str_mv | AT pinelopiargyriou theroleofmtorinhibitorsforthetreatmentofbcelllymphomas AT panagiotaeconomopoulou theroleofmtorinhibitorsforthetreatmentofbcelllymphomas AT sotiriospapageorgiou theroleofmtorinhibitorsforthetreatmentofbcelllymphomas AT pinelopiargyriou roleofmtorinhibitorsforthetreatmentofbcelllymphomas AT panagiotaeconomopoulou roleofmtorinhibitorsforthetreatmentofbcelllymphomas AT sotiriospapageorgiou roleofmtorinhibitorsforthetreatmentofbcelllymphomas |